DRG1 Inhibitors
DRG1 inhibitors represent a class of small molecules designed to specifically target and inhibit the activity of the DRG1 protein. DRG1, or Developmentally Regulated GTP-binding protein 1, is a member of the GTPase superfamily, which plays a pivotal role in cellular processes such as protein synthesis, ribosome biogenesis, and cell growth. These inhibitors are engineered to interfere with the normal functioning of DRG1, thereby affecting downstream signaling pathways and cellular events.
Chemically, DRG1 inhibitors are typically characterized by their ability to bind to DRG1 with high affinity, disrupting its GTPase activity. This inhibition results in the perturbation of the GTPase cycle of DRG1, impeding its ability to hydrolyze GTP to GDP, a critical step in its normal functioning. By interfering with this molecular switch, DRG1 inhibitors can potentially modulate protein synthesis and ribosome assembly, which are essential processes for cellular growth and homeostasis. These inhibitors can exhibit diverse chemical structures, and their design often involves computational approaches, structure-activity relationship studies, and high-throughput screening to identify compounds that possess the desired inhibitory properties against DRG1.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
NVP-AUY922 | 747412-49-3 | sc-364551 sc-364551A sc-364551B sc-364551C sc-364551D sc-364551E | 5 mg 25 mg 100 mg 250 mg 1 g 5 g | $150.00 $263.00 $726.00 $1400.00 $2900.00 $11000.00 | 3 | |
Luminespib is an HSP90 inhibitor that disrupts the chaperone function of HSP90, leading to proteasomal degradation of client proteins, including DRG1, and inhibiting its activity. | ||||||
AT13387 | 912999-49-6 | sc-364415 sc-364415A | 10 mg 50 mg | $555.00 $1606.00 | ||
AT13387 is an HSP90 inhibitor that destabilizes client proteins, including DRG1, resulting in proteasomal degradation and inhibition of its activity. | ||||||
KRIBB11 | 342639-96-7 | sc-507391 | 5 mg | $95.00 | ||
KRIBB11 disrupts the interaction between DRG1 and its target mRNA, inhibiting DRG1's role in ribosome assembly and protein translation. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
Torin 1 is an mTOR inhibitor that indirectly regulates DRG1 by inhibiting mTORC1, a downstream effector of mTOR, which phosphorylates DRG1. | ||||||
INK 128 | 1224844-38-5 | sc-364511 sc-364511A | 5 mg 50 mg | $321.00 $1835.00 | ||
MLN0128 is an mTOR inhibitor that inhibits mTORC1, leading to reduced phosphorylation and activation of DRG1. | ||||||
WYE-687 | 1062161-90-3 | sc-364653 sc-364653A | 10 mg 50 mg | $235.00 $992.00 | ||
WYE-687 is an mTORC1/2 dual inhibitor that directly inhibits mTORC1, leading to dephosphorylation and inactivation of DRG1. | ||||||
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $211.00 | 8 | |
NVP-BEZ235 is a dual PI3K/mTOR inhibitor that inhibits mTORC1, indirectly regulating DRG1 by blocking its phosphorylation and activation. | ||||||
AZD2014 | 1009298-59-2 | sc-364420 | 5 mg | $303.00 | 2 | |
AZD8055 is an mTOR inhibitor that directly inhibits mTORC1, leading to reduced phosphorylation and inactivation of DRG1. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTORC1 inhibitor that directly inhibits mTOR, which phosphorylates DRG1. Inhibition of mTORC1 results in reduced DRG1 activation. | ||||||
GSK2126458 | 1086062-66-9 | sc-364503 sc-364503A | 2 mg 10 mg | $265.00 $1050.00 | ||
GSK2126458 is an mTORC1/2 dual inhibitor that directly inhibits mTORC1, leading to reduced phosphorylation and inactivation of DRG1. | ||||||